Navigation Links
Cystic Fibrosis Trial In Children Returns Positive Data
Date:4/3/2008

SYDNEY, Australia, April 3, 2008 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis Ltd (ASX: PXS; Nasdaq: PXSL) announced today that a Phase II clinical trial in children with cystic fibrosis demonstrated excellent lung function improvement following three months treatment with Bronchitol that matched that achieved by the current marketed product rhDNase(1). The improvement in lung function after three months on Bronchitol reflects that seen in a previous study following two weeks of treatment.

The study was an independent investigator initiated study conducted in the United Kingdom in 20 children with a mean age of 13 years. Those children enrolled in the trial completed three months treatment with each of three different therapies - Bronchitol alone, both Bronchitol and rhDNase together and rhDNase alone. The trial measured changes in lung function, airway inflammation, infections, and quality of life.

At the end of the treatment period, lung function as determined by measuring FEV1 (the amount of air that can be forcibly exhaled in 1 second) improved by:

-- 7% while the subjects were on Bronchitol

-- 7% while subjects were on rhDNase and

-- 2% while subjects were on both agents together.

The study had insufficient numbers to reach a definitive statistical conclusion.

People affected by cystic fibrosis typically experience a decline in lung function of 1-2% every year of their life, as measured by FEV1.

Pharmaxis Chief Executive Officer Alan Robertson said: 'While not on the regulatory approval path, this is the first time we have had an opportunity to measure the performance of Bronchitol following 3 months continuous treatment and it bodes well for the pivotal 6 month Phase 3 trial that is currently in progress. Although the two agents worked less well when taken together, the patient numbers are low and a previous study has shown a benefit to using both therapies together.'

Bronchitol is des
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients
2. Genetic manipulation might model cystic fibrosis
3. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
4. Data show a decline in cystic fibrosis since introduction of prenatal carrier screening
5. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
6. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
7. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
8. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
9. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
10. Synosia Starts Phase II Efficacy Trial For Rufinamide
11. IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... November 24, 2014   ... ScienceDirect   Elsevier , a world-leading provider ... pleased to announce the launch of the latest title in ... Current Opinion in Food Science . ... specialists with a new platform to keep up-to-date with the ...
(Date:11/24/2014)... 24, 2014 The new video, ... METTLER TOLEDO demonstrates how to reduce the number ... and sample panel design can be complicated, requiring ... protect against corrosion and deposition. Dedicated single and ... amount of panel space. Additionally, installing and maintaining ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp was a ... with great people and take risks to achieve success. ... at his extraordinarily courageous attitude when taking on challenges. ... with his death impending—that’s how he continued looking for ... take his life. , Carrying on Sharp’s relentless dream ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by ... Glass, Plastic), by Application [GC, LC (HPLC, UHPLC, ... 2018” analyses and studies the major market drivers, ... Asia, and Rest of the World. , Browse ... through 135 pages and in-depth TOC on “Chiral ...
Breaking Biology Technology:Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... (GFP) in their retina cells or other tissues can ... real time computer record of movement and gene expression. ... BMC Biotechnology , will allow detailed analyses of ... Tower led a team of researchers from the University ...
... Washington Life Sciences Discovery,Fund (LSDF) has awarded nearly $4.7 ... Alliance (WAVA) and to support initial research into,three new ... the,grant is funded by Washington,s$350 million tobacco-lawsuit-settlement bonus,and provides ... , WAVA core ...
... Office has,issued Nutraceutix, Inc. a patent for BIO-tract. It ... the technology has been awarded based,on BIO-tract,s ability to ... their way to optimal release sites in the,intestinal tract. ... Nutraceutix comments: "Many years ago,we recognized the need for ...
Cached Biology Technology:Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 2Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 3Life Sciences Discovery Fund Awards $4.7 Million to Support New Vaccine Program 4Probiotic Delivery Technology Awarded Third International Patent 2
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
(Date:11/12/2014)... PALM BEACH GARDENS, Fla. , Nov. 12, 2014 ... management solutions, announced today that its U.are.U ® ... upscale retail bakery chain in Central Mexico ... solution in June 2014 to eliminate payroll issues caused ... Prior to installing the U.are.U fingerprint readers, Montparnasse ...
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... NEW YORK , Aug. 16, 2013   EyeLock Inc. , a ... of Roger An as Vice President of Global ... for research, analysis and strategic initiatives to further the embedded ... a heavy focus on Asia .   ...
... 2013) Primary results from a new clinical ... treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) ... islet cell function, compared to controls. Further analyses ... that demonstrated especially robust responses ("responders"), suggesting that ...
... body is a complicated system of blood vessels, nerves, organs, ... When all are working together, it,s a symphony of form ... Biologist Rejji Kuruvilla and her fellow researchers uncovered what happens ... along with graduate students Philip Borden and Jessica Houtz, both ...
Cached Biology News:EyeLock Appoints Roger An Vice President of Global Market Development 2EyeLock Appoints Roger An Vice President of Global Market Development 3ITN type 1 diabetes study identifies subset of patients with strong response to therapy 2ITN type 1 diabetes study identifies subset of patients with strong response to therapy 3Sympathetic neurons 'cross talk' with pancreas cells during early development 2Sympathetic neurons 'cross talk' with pancreas cells during early development 3
... designed for immunological studies, vaccine development, ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive Epitope ... Probe Content Probe content is ...
... Peptide microarrays containing peptidomimetics built on ... on-chip synthesis platform. These microarrays are ... Custom Peptide Microarray Service. ... is completely customer specified. Thousands of ...
... our Regulatory Edition of Molecular Imaging (MI) ... for life science research and drug discovery ... with U.S. Food and Drug Administrations Code ... Electronic Records; Electronic Signatures [21 CFR Part ...
... Now, for the first time, you ... faster and more efficiently without interferences. The ... to remove unwanted, multiple high-abundant proteins from ... with just one device. With this ...
Biology Products: